Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT

AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00.

Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector

A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.

AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted diluted EPS reaching $2.46, experiencing a 6.5% growth.

The company also reported $13.343 billion in net revenue for the first quarter of 2025, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.